Purpose: The TNF receptor superfamily member, CD27 is best known for its important role in T cell immunity, but is also recognized as a cell-surface marker on a number of B and T cell malignancies. In this report, we describe a novel human monoclonal antibody (mAb) specific for CD27 with properties that suggest a potential utility against malignancies that express CD27.
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CD22, CD30, CD38, CD40, CD45, CD70, CD74, and CD80 that are in clinical development as listed in clinicaltrials.gov. Importantly, although the side effect hypogammaglobulinemia has been observed with rituximab, the presence of the targeted receptors on both the malignant cells as well as the normal counterparts has not caused significant limitations to these approaches.
The TNF receptor superfamily member, CD27, is a tightly regulated co-stimulatory molecule activated by ligation through its unique counter-receptor, CD70 (3) . In humans, CD27 is expressed on the surface of the majority of T cells, memory B cells and plasma cells, and some NK cells (4) (5) (6) . The interaction of CD27 with CD70 plays an important role in the activation, proliferation, and survival of T cells; in clonal B cell expansion and germinal center formation; and in NK cell cytolytic activity (7-10). Recent studies show that modulation of this pathway by engineered expression of CD70 or agonist anti-CD27 antibodies can overcome tolerance and circumvent CD40-mediated signaling, leading to anti-tumor immunity in experimental systems (11) (12) (13) (14) . In addition, expression of CD70 on lymphoma and other experimental tumor cell lines has been shown to promote their rejection by both NK and T cell dependent mechanisms in immunocompetent mouse tumor models (15, 16) , and CD27 activation is critical for the appropriate generation of anti-leukemia T cell response in B cell precursor acute lymphoblastic leukemia (17) .
The expression of CD27 on various types of lymphomas and leukemias has been well documented (18) (19) (20) (21) (22) (23) . CD27 expression is present on most B cell malignancies at varying levels, and is also expressed by adult T-cell leukemia/lymphoma (18, 19, 24) . An important observation has been the correlation of tumor burden in patients with acute and chronic B-cell malignancies and levels of a soluble form of the receptor, sCD27 that is presumably released by enzymatic cleavage (18) . Despite the abundance of CD27 on these tumors, we are not aware of any efforts to develop therapeutic anti-CD27 antibodies for potential use in patients with lymphoma or leukemia.
To determine if CD27 is a potential therapeutic target for antibody therapy of CD27-expressing tumors, we developed a fully human monoclonal antibody by use of human immunoglobulin expressing mice (25) . In this study, we report the characterization of this human anti-CD27 antibody's activity in vitro and in xenograft models with human lymphoma cell lines. In addition, we investigated the feasibility of this approach by administering the antibody to non-human primates. The human anti-CD27 antibody, 1F5, shows potent anti-tumor activity and does not result in direct T cell activation or significant depletion of CD27+ lymphocytes in vivo and represents a novel opportunity for testing in clinical trials. 
CD27 ELISA
The CD27 ELISAs were performed using purified rhesus macaque CD27 (rhesus and cynomolgus are identical in the amino acid sequence of the extracellular domain) or human CD27. Briefly, we cloned the extracellular domain of CD27 from mRNA isolated from macaque or human PBMC by RT-PCR. The CD27 cDNA was introduced in a mammalian expression vector as an in-frame fusion protein with human kappa light chain for secretion and purification, and a FLAG-tag sequence was added at the C-terminus.
The vectors were used for transient transfection of HEK 293 FreeStyle cells, and supernatants collected for purification by protein L chromatography. Purified macaque CD27 or human CD27 was captured to ELISA plates with anti-FLAG antibody, followed by incubation with anti-human CD27 mAb. A goat anti-human IgG Fc-HRP antibody and substrate Super Blue TMB were used for detection.
Samples were analyzed at OD 450 using a microtiter plate reader and IC 50 were derived by using software SoftMax Pro V5. Specificity of IF5 for CD27 was examined by ELISA using microtiter plates coated with other TNFR superfamily members, 4-1BB, CD40, Fas and TNFRSF1A (R&D Systems, Minneapolis, MN) and their respective antibodies for positive controls.
Biacore analysis
Binding affinity and binding kinetics 1F5 was examined by surface plasmon resonance (SPR) analysis using a Biacore 2000 SPR instrument (Biacore AB, Uppsala, Sweden) according to the manufacturer's guidelines. CD27/Fc (R&D Systems, Minneapolis, MN) was covalently linked to a Biacore CM5 sensor chip using standard amine coupling 
Proliferation and Cytokine induction
For proliferation studies, anti-CD3 mAb (OKT3) was added to the wells of a 96 well tissue culture plate with 1F5 mAb or huIgG1 isotype control in a final volume of 50L.
The antibodies were allowed to dry overnight in the well. In selected wells, the 1F5 mAb or huIgG1 isotype control was added in aqueous solution to the previously coated anti- 
Statistical analyses
Statiscal analysis on the xenograft experiments were performed using Wilcoxon twosample test analysis and the Kaplan-Meier MedCalc software program. 
Human mAb 1F5 binding characteristics
The human anti-CD27 IgG1antibody 1F5 was confirmed to contain somatic mutations in the complementarity determining regions of both the heavy and light chains, and was purified for further characterization. The 1F5 mAb has strong reactivity with three human Burkitt's lymphoma cell lines, Raji, Daudi, and Ramos ( Figure 1A) , and efficiently blocked the interaction between CD70 and CD27, suggesting an epitope specificity in the ligand binding domain ( Figure 1B The selection of 1F5 mAb was partly based on cross-reactivity to macaque CD27 that could provide a critical model for establishing the safety and functional characteristics of antibodies with potential clinical utility. For this purpose, we cloned and expressed the extracellular domain of CD27 from human, rhesus macaque and cynomolgus macaque PBMCs. The amino acid sequence for rhesus and cynomolgus macaque was identical and therefore interchangeable for these species. An ELISA assay demonstrating similar binding of 1F5 to CD27 from human and macaques is shown in Figure 1C . The concentration yielding 50% of maximum binding (IC 50 ) of 1F5 was 0.059 g/ml, and 0.12 g/ml for human and macaque CD27, respectively. To further establish the relevance of macaques as a model for testing 1F5, we compared the binding pattern of 1F5 to peripheral blood lymphocytes from 6 individual humans and monkeys (Table 1) 
and thus appear to reflect real differences and similarities in CD27 expression patterns between the two species (data not shown).
1F5 mAb inhibits the growth of transplantable human lymphoma cells in SCID mice
The selection of the 1F5 mAb was also based on its ability to inhibit the growth of CD27-expressing tumors in xenograft models. To assess the anti-tumor activity of 1F5, we administered the antibody to immunodeficient SCID mice after inoculation with human Burkitt's lymphoma derived Raji or Daudi cells. Relatively low doses of antibody were effective in significantly retarding the growth of the subcutaneously implanted Raji cells and improved survival (Figure 2A and 2B) . Interestingly, the trend toward lower efficacy at higher 1F5 dose was consistently observed in Raji xenograft model. However, this was not observed in other tumor xenograft models, which showed similar or better activity at the 0.3 mg dose (data not shown). Similarly, 1F5 had significant effect on the survival of mice in a disseminated tumor model using intravenous inoculation of Daudi cells ( Figure 2C ).
Effector functions of 1F5 mAb
The anti-tumor effects of 1F5 in the SCID xenograft models suggest that 1F5 can mediate effector functions such as ADCC or complement dependent cytotoxicity (CDC), and/or might lead to direct inhibition of tumor cell growth through induction of apoptosis.
Although 1F5 mAb is an IgG1 mAb, an isotype capable of efficient complement fixation,
we were unable to demonstrate significant CDC activity against the lymphoblastoid cell Similarly, 1F5 did not appear to have significant effects on the growth or apoptosis of these cell lines in vitro (data not shown). However, we observed significant ADCC activity of 1F5 using human PBMC effector cells and Ramos or Daudi tumor cells ( Figure 2D) . This suggests that ADCC may be the dominant mechanism for the activity of 1F5 in the xenograft models.
Effect of 1F5 on human lymphocytes in vitro
We used in vitro assays with human PBMC or purified T cells to address the potential concern that the engaging CD27 with 1F5 on human lymphocytes could lead to nonspecific proliferation and cytokine release. Consistent with the known biology of CD27 we demonstrated the 1F5 mAb does not lead to direct activation of lymphocytes in the absence of additional signals. 1F5 was unable to activate human lymphocytes to divide ( Figure 3A, left panel) even under conditions that favor maximum cross-linking of the receptor (coated wells). However, combining 1F5 with suboptimal levels of T cell receptor stimulation using anti-CD3 mAb (OKT3) was shown to enhance proliferation of human T cells ( Figure 3A, right panel) . The 1F5 mediated proliferation required the antibody to be immobilized, suggesting the requirement for cross-linking. Similarly, the combination of 1F5 and OKT3 also led to significant IFN- and TNF- from both CD4 and CD8 T cells using intracellular cytokine analysis ( Figure 3B ). These data are consistent with the requirement for a second signal via the T cell receptor for CD27 mediated signaling to induce T cell activation (27, 28), and confirm the agonist properties of 1F5 mAb. 
Effect of 1F5 on circulating lymphocytes in monkeys
A preliminary in vivo study was conducted to assess the potential of 1F5 to cause lymphocyte activation or depletion that may result in safety concerns. Three male circulating lymphocytes by staining cells with anti-human IgG (Figure 5B) . Even at the lowest dose of 1 mg/kg, the lymphocytes and memory B cells were saturated with 1F5 throughout the 29 day study. This was not surprising as low levels of circulating antibody could still be detected in this animal at day 29 (0.25 g/ml).
Discussion
Although the expression of CD27 on various lymphomas and leukemias is well documented, we are not aware of reports that address the potential of CD27 as a direct therapeutic mAb target. Here we have described the characterization of a new human anti-CD27 mAb, 1F5, which was selected from a panel of fully human anti-CD27 antibodies generated using human Ig transgenic mice. We selected 1F5 mAb due to its high affinity for CD27, cross-reactivity with rhesus and cynomolgus macaque CD27, and activity in several in vivo models. In addition, 1F5 was shown in competition assays to bind at the ligand binding domain of CD27, which may improve its ability to mimic the ligand mediated receptor cross-linking.
The therapeutic potential of 1F5 was demonstrated in xenograft models using human lymphoblastoid cell lines grown in SCID mice. Mice treated over the range of 33-300 g 1F5 mAb per dose x 6 (approximately 1.5 -15 mg/kg) showed a significant reduction in subcutaneous Raji tumor cell growth and complete eradication in a small proportion of the mice. Importantly, the 1F5 treatment was also effective in improving the survival of mice using a disseminated model of i.v. administered Daudi lymphoma cells. In these models, the antibody can only react with CD27 on the human tumor cells, due to the lack 
of any binding by 1F5 to mouse CD27 (data not shown), suggesting that the anti-tumor activity is based on effector mechanisms such as ADCC, CDC, or growth inhibition/apoptosis via CD27 signaling in tumor cells. In addition, we have observed significant ADCC with the 1F5 mAb using several human lymphoma cell lines. In contrast, we did not observe significant CDC, apoptosis or direct growth inhibition under the conditions of the experiments we performed.
Recent studies have documented the potential for anti-CD27 antibodies in mouse lymphoma models (11, 13, 14). Interestingly, in these studies, the primary mechanism of 
The effector functions and agonistic properties of 1F5 prompted concern that the antibody may result in depletion of T cells and/or non-specific activation that could limit the therapeutic utility and generate unwanted side-effects. We demonstrated the 
